中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 11
Nov.  2021
Turn off MathJax
Article Contents

Clinical features of drug-induced liver failure and related diagnosis and treatment strategies

DOI: 10.3969/j.issn.1001-5256.2021.11.006
Research funding:

National Natural Science Foundation of China (82070604);

National Natural Science Foundation of China (81770587);

National Natural Science Foundation of China (81970514);

Shanghai Municipal Planning Commission of science and Research Fund (202040111);

Shanghai Municipal Key Clinical Specialty (shslczdzk01103);

Major Projects of the Ministry of Science and Technology during the 13th Five-Year Plan period (2017ZX10203201-008);

Major Projects of the Ministry of Science and Technology during the 13th Five-Year Plan period (2018ZX09201016-003-001);

Major Projects of the Ministry of Science and Technology during the 13th Five-Year Plan period (2017ZX10202202-005-004)

  • Received Date: 2021-09-15
  • Accepted Date: 2021-09-15
  • Published Date: 2021-11-20
  • The incidence of drug-induced liver injury (DILI) has risen considerably in recent years. Drug-induced liver failure tends to have severe conditions, limited therapeutic strategy, and a high mortality rate and should thus be taken seriously by clinicians. N-acetyl-p-aminophenol is the most common cause of acute liver failure (ALF) in Western countries; for ALF associated with idiosyncratic DILI (iDILI), since there is little in-deep understanding of host susceptibility and pathogenesis, it is difficult to identify ALF caused by iDILI in the early stage, and due to a low rate of spontaneous recovery and poor prognosis, it has become a major indication for emergency liver transplantation in many countries. A comprehensive understanding of the clinical features and prognostic prediction of drug-induced liver failure and the search for new reliable diagnostic methods and effective treatment strategies are of vital importance in reducing the disease burden of drug-induced liver failure.

     

  • loading
  • [1]
    REUBEN A, TILLMAN H, FONTANA RJ, et al. Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study[J]. Ann Intern Med, 2016, 164(11): 724-732. DOI: 10.7326/M15-2211.
    [2]
    REUBEN A, KOCH DG, LEE WM. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study[J]. Hepatology, 2010, 52(6): 2065-2076. DOI: 10.1002/hep.23937.
    [3]
    CRAIG DG, BATES CM, DAVIDSON JS, et al. Overdose pattern and outcome in paracetamol-induced acute severe hepatotoxicity[J]. Br J Clin Pharmacol, 2011, 71(2): 273-282. DOI: 10.1111/j.1365-2125.2010.03819.x.
    [4]
    SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11. DOI: 10.1053/j.gastro.2019.02.002.
    [5]
    SGRO C, CLINARD F, OUAZIR K, et al. Incidence of drug-induced hepatic injuries: A French population-based study[J]. Hepatology, 2002, 36(2): 451-455. DOI: 10.1053/jhep.2002.34857.
    [6]
    HILLMAN L, GOTTFRIED M, WHITSETT M, et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury[J]. Am J Gastroenterol, 2016, 111(7): 958-965. DOI: 10.1038/ajg.2016.114.
    [7]
    MURRAY KF, HADZIC N, WIRTH S, et al. Drug-related hepatotoxicity and acute liver failure[J]. J Pediatr Gastroenterol Nutr, 2008, 47(4): 395-405. DOI: 10.1097/MPG.0b013e3181709464.
    [8]
    TREY C, DAVIDSON CS. The management of fulminant hepatic failure[J]. Prog Liver Dis, 1970, 3: 282-298.
    [9]
    TANDON BN, BERNAUAU J, O'Grady J, et al. Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure[J]. J Gastroenterol Hepatol, 1999, 14(5): 403-404. DOI: 10.1046/j.1440-1746.1999.01905.x.
    [10]
    CRAIG DG, ZAFAR S, REID TW, et al. The sequential organ failure assessment (SOFA) score is an effective triage marker following staggered paracetamol (acetaminophen) overdose[J]. Aliment Pharmacol Ther, 2012, 35(12): 1408-1415. DOI: 10.1111/j.1365-2036.2012.05102.x.
    [11]
    BERNAL W, AUZINGER G, DHAWAN A, et al. Acute liver failure[J]. Lancet, 2010, 376(9736): 190-201. DOI: 10.1016/S0140-6736(10)60274-7.
    [12]
    REDDY KR, ELLERBE C, SCHILSKY M, et al. Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States[J]. Liver Transpl, 2016, 22(4): 505-515. DOI: 10.1002/lt.24347.
    [13]
    ANDRADE RJ, LUCENA MI, FERNÁNDEZ MC, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period[J]. Gastroenterology, 2005, 129(2): 512-521. DOI: 10.1016/j.gastro.2005.05.006.
    [14]
    BERNUAU J, BENHAMOU JP. Classifying acute liver failure[J]. Lancet, 1993, 342(8866): 252-253. DOI: 10.1016/0140-6736(93)91809-z.
    [15]
    RIORDAN SM, WILLIAMS R. Liver disease due to illicit substance use[J]. Addict Biol, 1998, 3(1): 47-53. DOI: 10.1080/13556219872335.
    [16]
    WAI CT, TAN BH, CHAN CL, et al. Drug-induced liver injury at an Asian center: A prospective study[J]. Liver Int, 2007, 27(4): 465-474. DOI: 10.1111/j.1478-3231.2007.01461.x.
    [17]
    SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3.
    [18]
    SARIN SK, KUMAR A, ALMEIDA JA, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)[J]. Hepatol Int, 2009, 3(1): 269-282. DOI: 10.1007/s12072-008-9106-x.
    [19]
    DEVARBHAVI H, CHOUDHURY AK, SHARMA MK, et al. Drug-induced acute-on-chronic liver failure in Asian patients[J]. Am J Gastroenterol, 2019, 114(6): 929-937. DOI: 10.14309/ajg.0000000000000201.
    [20]
    HERNAEZ R, SOLÀ E, MOREAU R, et al. Acute-on-chronic liver failure: An update[J]. Gut, 2017, 66(3): 541-553. DOI: 10.1136/gutjnl-2016-312670.
    [21]
    TESCHKE R, SCHULZE J, EICKHOFF A, et al. Drug induced liver injury: Can biomarkers assist RUCAM in causality assessment?[J]. Int J Mol Sci, 2017, 18(4): 803. DOI: 10.3390/ijms18040803.
    [22]
    BENICHOU C, DANAN G, FLAHAULT A. Causality assessment of adverse reactions to drugs—Ⅱ. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge[J]. J Clin Epidemiol, 1993, 46(11): 1331-1336. DOI: 10.1016/0895-4356(93)90102-7.
    [23]
    KLEINER DE, CHALASANI NP, LEE WM, et al. Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations[J]. Hepatology, 2014, 59(2): 661-670. DOI: 10.1002/hep.26709.
    [24]
    KEAYS R, HARRISON PM, WENDON JA, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial[J]. BMJ, 1991, 303(6809): 1026-1029. DOI: 10.1136/bmj.303.6809.1026.
    [25]
    NABI T, NABI S, RAFIQ N, et al. Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study[J]. Saudi J Gastroenterol, 2017, 23(3): 169-175. DOI: 10.4103/1319-3767.207711.
    [26]
    HU J, ZHANG Q, REN X, et al. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials[J]. Clin Res Hepatol Gastroenterol, 2015, 39(5): 594-599. DOI: 10.1016/j.clinre.2015.01.003.
    [27]
    RAKELA J, MOSLEY JW, EDWARDS VM, et al. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group[J]. Dig Dis Sci, 1991, 36(9): 1223-1228. DOI: 10.1007/BF01307513.
    [28]
    MINDIKOGLU AL, MAGDER LS, REGEV A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: Analysis of the United Network for Organ Sharing database[J]. Liver Transpl, 2009, 15(7): 719-729. DOI: 10.1002/lt.21692.
    [29]
    CHOUDHARY NS, SAIGAL S, SARAF N, et al. Good outcome of living donor liver transplantation in drug-induced acute liver failure: A single-center experience[J]. Clin Transplant, 2017, 31(3): e12907. DOI: 10.1111/ctr.12907.
    [30]
    LAI R, XIANG X, MO R, et al. Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury[J]. J Hepatol, 2015, 63(1): 148-155. DOI: 10.1016/j.jhep.2015.02.004.
    [31]
    MCPHAIL MJ, FARNE H, SENVAR N, et al. Ability of King's College Criteria and Model for End-Stage Liver Disease scores to predict mortality of patients with acute liver failure: A Meta-analysis[J]. Clin Gastroenterol Hepatol, 2016, 14(4): 516-525. e5; quiz e43-e45. DOI: 10.1016/j.cgh.2015.10.007.
    [32]
    KOCH DG, TILLMAN H, DURKALSKI V, et al. Development of a model to predict transplant-free survival of patients with acute liver failure[J]. Clin Gastroenterol Hepatol, 2016, 14(8): 1199-1206. e2. DOI: 10.1016/j.cgh.2016.03.046.
    [33]
    ROBLES-DIAZ M, LUCENA MI, KAPLOWITZ N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury[J]. Gastroenterology, 2014, 147(1): 109-118. e5. DOI: 10.1053/j.gastro.2014.03.050.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (538) PDF downloads(227) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return